108 results
S-8
EX-4.3
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
provide Continuous Service (the “Service Recipient”) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment
S-8
EX-4.6
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
it is terminated.
Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension
S-8
EX-4.2
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
when calculating any Participant’s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise
S-8
EX-4.4
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
”) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items associated
S-8
EX-4.5
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
benefits tax, payment on account or other tax-related items associated with the grant or vesting of the Restricted Stock Award or sale of the underlying
8-K
EX-99.1
s3muo5t5
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
8-K
EX-99.1
mqrxeic
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
424B5
cie5uin1k5vt 8u
1 Mar 24
Prospectus supplement for primary offering
4:13pm
8-K
EX-1.1
uevady mj6268p0ingnd
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
424B5
y6rur
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
5gz4j5
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
8-K
EX-99.1
5pxpp1fo059sv
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
h2idq6oe
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
fna6pzqap0b
26 Jul 23
Automatic shelf registration
5:26pm
S-3ASR
EX-5.1
tyx 1qjx40s16grfp
26 Jul 23
Automatic shelf registration
5:26pm